

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Zheng Xin Dong *et al.*

Application No.: 09/674,597

Group Art Unit: Unknown

Filed: November 2, 2000

Examiner: Unknown

RECEIVED

MAY 15 2001

TECH CENTER 1600/2900



Title: PTH2 RECEPTOR SELECTIVE COMPOUNDS

CERTIFICATE OF MAILING

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Date of Deposit: April 27, 2001

Karen Loudon

Karen Loudon

INFORMATION DISCLOSURE STATEMENT AND AUTHORIZATION TO
CHARGE DEPOSIT ACCOUNT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within three months of filing national application; or date of entry of the national stage in international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$240.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a Petition under 37 CFR 1.97(d)(2), and

☐ a \$130.00 petition fee set forth in 37 CFR 1.17(i).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

☐ Applicant requests that the attached IDS and cited reference(s) ☐ be placed in the application filewrapper.

(Filed after payment of issue fee)

☒ The listed references were cited in the enclosed Search Report which issued in connection with the corresponding International Patent Application.

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449, with copies of the references noted thereon; with a Certificate of Mailing.
- ☐ Copies of the reference(s) noted on the enclosed form 1449 were previously cited by or submitted to the Patent and Trademark Office in connection with U.S. Application Serial No. [], from which the present application claims benefit under 35 U.S.C. § 120 (37 C.F.R. 1.98(d)).

Concise Explanation Requirement (non-English references):

- ☐ The "concise explanation" requirement for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ the enclosed English language abstracts.

It is requested that the information disclosed herein be made of record in this application, and that the references listed on the enclosed form PTO-1449 appear under the "References Cited" heading of any Patent which issues from this application, (MPEP 1302.12).

Method of payment:


- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply.
- ☒ No fee is believed to be due for this submission. However Applicant(s) hereby authorize the Assistant Commissioner to charge any fees that may be deemed to be due or to credit any overpayment to Deposit Account No. 50-0590. Two copies of this Statement are enclosed.
- ☒ The Assistant Commissioner is hereby authorized to please charge any deficiency in fees and credit any overpayment to Deposit Account 50-0590. Two copies of this Statement are enclosed.

Respectfully submitted,

BIOMEASURE, INCORPORATED

Dated: 4-27-2001

By


Alan F. Feeney, Attorney for Applicant(s)

Registration No.: 43,609

Telephone: (508) 478-0144

Facsimile: (508) 473-3531

Certificate of mailing by first class mail (37 CFR 1.8)
Applicant(s): Zheng Xin Dong et al.

Docket No.
00537/169002

Serial No.

09/674,597

Filing Date

November 2, 2000

Examiner

Unknown

Group Art Unit

Unknown

Invention:

PTH2 RECEPTOR SELECTIVE COMPOUNDS

I hereby certify that this PTO-1449 Form

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231

on

April 27, 2001
(Date)

Karen Louden

(Typed or Printed Name of Person Mailing Correspondence)

Karen Louden
(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of Mailing.



PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
00537/169002APPLICATION NO.
09/674,597APPLICANT
Zheng Xin DongFILING DATE
November 2, 2001GROUP
Unknown

RECEIVED

MAY 15 2001

TECH CENTER 1600/

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
✓	AL	WO 92/11286	09 Jul 1992	PCT			
✓	AM	WO 97/02834	30 Jan 1997	PCT			
✓	AN	WO 98/14478	09 Apr 1998	PCT			
✓	AO	EP 0 477 885	25 Sep 1991	Europe			
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AR	GARDELLA, Thomas J. et al.; "Converting Parathyroid Hormone-related Peptide (PTHrP) into a Potent PTH-2 Receptor Agonist"; Journal of Biological Chemistry, US, American Society of Biological Chemists, Baltimore, MD,; Vol. 271, No.: 33 Pgs 19888-19893; (1996)
✓	AS	USDIN, Ted B.; "Evidence for a Parathyroid Hormone-2 receptor selective ligand in the hypothalamus" Endocrinology, Vol. 138, No. 2, Pgs. 831-834; (1997)
✓	AT	BEHAR, V. et al.; "Histidine at Position 5 Is the Specificity "Switch" between Two Parathyroid Hormone Receptor Subtypes"; Endocrinology Vol. 137, No. 10; Pgs. 4217-4224; (1996)

EXAMINER

DATE CONSIDERED